The pharmaceutical sector is undergoing a fundamental transformation driven by the convergence of digital health technologies, real world evidence, customer relationship management systems, artificial intelligence, and increasingly stringent data governance frameworks. At the heart of this transformation lies the need to move pharmacovigilance from a reactive, compliance driven activity to a proactive, intelligence driven strategic capability that supports patient safety, regulatory trust, and sustainable commercial success. This research article develops an original and integrative conceptual and empirical analysis that links strategic integrated evidence generation planning, modern pharmaceutical CRM architectures, FAIR data principles, and AI enabled pharmacovigilance into a unified governance and operational model. Drawing strictly on contemporary and foundational literature, including the Medical Affairs Professional Society guidance on integrated evidence generation, relationship marketing theory, advanced data governance scholarship, and cutting edge pharmacovigilance research, this study demonstrates how pharmaceutical organizations can create a learning health system that continuously converts patient experiences into regulatory grade evidence and strategic customer insights.

The study argues that traditional siloed approaches to evidence generation, safety monitoring, and customer engagement are no longer viable in an environment characterized by real time data streams, complex regulatory expectations, and highly informed healthcare stakeholders. Instead, pharmaceutical firms must adopt strategic evidence ecosystems in which clinical trial data, post marketing surveillance, electronic health records, patient registries, wearable devices, and social media analytics are systematically integrated through interoperable CRM platforms and governed by robust data stewardship frameworks. Within such systems, pharmacovigilance becomes an embedded intelligence function that not only detects adverse drug reactions but also informs product lifecycle management, risk mitigation strategies, and value based healthcare partnerships.